June 29-30, 2021 | Virtual Event

Agenda

Come visit our virtual lobby and connect with fellow attendees. You can chat, video, and even make a list of the people you want to meet and the knowledge you’re looking to gain through our bespoke 1:1 match-making services.
Technology must not just be “cool” or “innovative”, it must have concrete evidence that it either improves patient outcomes or reduces cost (or ideally both). As in the case of the analog world, concrete evidence of value will rule the day in digital.

  • Understanding the challenges involved with designing, building, and implementing digital and innovation strategy for Medical Affairs
  • Integrate digital culture change management by identifying and aligning on digital priorities
Robert Stevens
Vice President, Global Head Digital Medical Affairs
NOVARTIS
Necessity is the mother of invention” (Plato). COVID-19 has been a driver of the need for medical affairs to employ new and digital approaches to stakeholder engagement and insight gathering. For the many small- to mid-sized companies that were not already on a path to digital adoption, the pandemic has changed the question of organizational buy-in for new digital tools and strategies from ‘should we?’ to ‘how can we?’ This session is a case study in how to approach moving from an analog to digitally-capable medical organization.

Key elements:
  • Discuss steps to go from zero to digital
  • Identify a framework to consider the landscape of medical affairs digital engagement opportunities
  • Discuss strategic medical plan development for digital engagement
Barry Lubarsky
Executive Director, Medical Affairs Strategy, 
ALKERMES
  • Leveraging technology and dashboards as effective project management and communication tools
  • Delivering creative content and ensuring efficient virtual conference experiences
  • Ensuring high quality and effective virtual KOL exchange
  • Complementing a clinical program with RWE/HEOR studies that leverage digital
Gigi Shafai
Former Medical Affairs Executive
CATABASIS PHARMACEUTICALS
A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts and conference speakers.
  • Addressing key priorities driving a collaborative culture between medical affairs and commercial to improve customer experience, business efficiencies
  • Increasing communication to be more forward-looking and ensure a greater understanding of the needs and preferences of their internal and external audiences
  • Incorporating innovative partnerships both internally and externally with start-up companies and larger tech companies in the digital ecosystem to transform:
    • (1) External customer engagement across a variety of stakeholders including HCPs and patients
    • (2) Use of digital technology and sensors to optimize clinical trials & data generation
    • (3) Incorporation of digital capabilities through systems, platforms, and applications to optimize efficiency across internal functions.
Brandee Paknis
Vice President, Global Medical Affairs Digital Innovation and Excellence
NOVARTIS
  • Understand how the medical affairs function is evolving to meet the needs of healthcare providers and their patients
  • Review actionable, innovative, and data-driven tactics to enhance the value proposition of medical affairs
  • Learn how to leverage AI and data for a more effective and efficient approach to field medical operations
Andrew Rosen
Director of Global Data Generation
AKCEA THERAPEUTICS
  • Partnering with compliance and regulatory colleagues to ensure that social media are being used in an appropriate way
  • Understanding Social Media advantages over traditional data-gathering to gather valuable insights including discussions around key scientific topics, perspectives on recent data releases, and commentary on new product launches
  • Engages KOLs on Social Media Social media to enable Medical Affairs to find potential opinion leaders—digital opinion leaders, or DOLs—to develop a relationship with.
  • Why measuring impact matters?
  •  The digital transformation of medical affairs KPIs
  •  Omni-channel engagements and metrics
  •  A new model to measure the value of medical teams
  •  Predictions on value proposition of medical affairs
Luca Dezzani
VP, US Medical Affairs,
EISAI
A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts and conference speakers.
  • Creating a customer-centric culture to measure and improve engagement
  • Using data to drive action throughout the organisation
  • Delivering a data-driven, customer-centric experience that flows seamlessly across channels and devices
  • How to improve the engagement experience from medical communications
  • Attaching an ROI to engagement: how to measure the engagement experience vs. engagement scores
  • Measuring medical impact through analytics
  • Getting internal buy in and aligning on priorities for overlapping digital initiatives with medical and commercial
  • Creating demand for and getting buy in to digital modalities across the business
  • Connecting HCPs to reputable and independent sources by leveraging the technology that is now widely available to develop collaborative and open innovation
  • Bringing key insights to critical teams and committees earlier to ensure that plans and investment decisions throughout the treatment’s lifecycle are robust and evidence-based from the start
  • Utilizing wearables and smart devices to capture data points that were not collected before
Jill White
Director, Medical Affairs Excellence
ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA)
  • Understanding the arrival of ‘disruptive’ trends such as real-world data, sensors, artificial intelligence, precision medicine and physician communities to further accelerate the strategic importance of eMedical programmes across the product life cycle
  • Starting multichannel medical education during phase II/III to establish unmet needs, thought leader advocacy, a strong medical platform and the core scientific positioning of the product to maximise uptake at launch
  • Maximize data and messages dissemination for uptomial product awareness via the full range of multichannel vehicles to address internal and external audiences
  • Understanding the element of multichannel, what does it mean to be effective in a phone, email, skype
Wagdy Youssef
Senior Director US Medical Communication, Medical Information, Publication and Digital Transformation
BAYER
A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speakers may have questions for you as well!
Come visit our virtual lobby and connect with fellow attendees. You can chat, video and even make a list of the people you want to meet and knowledge you’re looking to gain through our bespoke 1:1 match-making services.
  • Harnessing Zoom video conferencing tools for internal and external group meetings to save time and effort with little difficulty
  • Deploying digital tools to deliver patient activation initiatives that can be tracked and measured via validated tools
  • Making content usable in different formats to suit physicians’ busy lives that helps them answer clinical questions quickly
Sheetal Patel
Medical Strategy Lead, US Medical
LUNDBECK
  • Using virtual advisory board to increase interaction with key opinion leaders (KOLs)
  • Implement a new way of communication allowing KOLs to provide advice to pharmaceutical companies without disrupting clinical workflow
  • Utilizing Telemedicine or Virtual consultation to enhance patient experience and engagement
  • Understand new ways MSLs can collect insights without interacting with HCPs directly
Panelists:
Bernard Ng
VP Head of Global Medical and  Clinical Affairs for Bayer Consumer Healthcare,
BAYER

Kunj Gohil
Director, Digital Strategy Lead [New Engagement Models] - Global Medical Affairs 
NOVARTIS
  • Collecting, organizing, and translating insights into actionable inputs that can inform the medical strategy
  • Applying AI to help to process insights from different sources and make them available to medical affairs professionals in a format that simplifies the interpretation and make it easier to find patterns that are informative for the company
  • Predicting what contents are of highest interest to each Heath Care Professional (HCP) and implementing a feedback loop that will make the content more useful and personalized in real time.
Reza Safaei, MD
Vice President, Head of Medical Affairs International
APELLIS PHARMACEUTICALS
A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speakers may have questions for you as well!
Everyone digests information differently and have different preferences on how they like to receive information and learn. Understand the audience you want to reach, how they learn in the digital age, and how to increase their engagement via digital content.

  • Conduct market research to find out who your audience is
  • Reach out to KOL base and identify where they go for their information
  • Have a dynamic feedback loop with customers to gain insights
  • Develop tailored digital innovation to cater to specific audiences for digital content
  • Examine which digital assets best fit the data type/scientific messages and are most effective to reach goals for successful ROI
  • Link metrics to digital assets to understand which content is most engaging to apply learnings for updating and/or developing digital assets
Many medical affairs teams underestimate the value of the data that they create and consume. The utility of analytics is often misunderstood and developing a data strategy can be overwhelming. As biotech embraces more digital solutions, an investment into data-driven decision making and a self-service analytics model becomes crucial in showcasing ROI and value.

  • Understand the gaps, opportunities, data silos, and current data landscape of your team
  • Start small and utilize a structured framework to bring data to the hands of your users to increase adoption and create a data-oriented department
  • Avoid investing in “shiny” AI/ML vendors or projects without having a defined ROI and business use case
  • Case Study 1: Natural Language Processing in Medical Information & Field Medical
  • Case Study 2: Descriptive/Predictive Capabilities of Medical-Legal-Regulatory data in Medical Affairs Operations
Imtiyaz Hossain
Associate Director, Data Science Lead, Global Medical Affairs
TAKEDA
  • Ensuring fast, efficient, and meaningful responses to all stakeholders using digital tools to bring agility and customer centricity
  • Achieve greater cross functional collaboration to remove regulatory hurdles and evolve the measurement framework
  • Optimizing customer experience for each person using a rich dataset to adapt and adjust the experience for each person
  • Learning the difference between digital strategy vs. digital Transformation to Develop a Deep Understanding of how Changes will Affect Customer Experience
Dotan Ran
Director, Innovation and Capabilities, Medical & Scientific Affairs
MERCK
  • Understanding why digital transformation mean simply transformation of PEOPLE to accept digital technology
  • Unlocking  human potential and creating an organization that’s open to change, resilient to risk, and fit for the future
  • Overcoming the top challenges to digital transformation and find a path to success
Raweesh Chaudhary
Director, Medical Affairs (Cardiovascular and Metabolic Diseases) 
ASTRAZENECA
  • Developing Big Data and real-world evidence to support drug development, including real-world evidence, in-house data and scientific analysis
  • Leveraging deep relationships with prescribers and opinion leaders and continually collecting feedback and signals from the market to provide critical input to drug development and life cycle management from early identification of promising compounds through post-launch market strategies
  • Using scientific data to cut through the marketing noise and profile its product fairly vs. the new entrant
  • Establishing a digital engagement task force that includes both home office and field medical teams as well as cross-functional team members with a defined structure, capability and mandate to make rapid decisions
  • Use Artificial Intelligence, such as machine learning, block-chain and algorithms to uncover disease state opportunities, accelerate and synthesize insights from real world data
  • Using downtime that field teams may currently be experiencing to upskill your people with necessary digital capabilities and proactively establish customer feedback mechanisms to facilitate test/learn/iterate rollout approaches moving forward
  • When and when not to use Digital in Medical Affairs
Vivek Thakkar
Regulatory Program Director - Personalized Healthcare - Digital Health
GENENTECH/ROCHE
  • Discuss emerging trends and viewpoints on the next frontier for digital in Medical Affairs and the broader healthcare environment with the “New Normal”
  • Explore “outside-in” views on how leading technology companies are addressing the COVID-19 scenario with new approaches across pharma and other industries
  • Identify how the disruption can be turned into opportunities and differentiating strategies
  • Leading medical digital work steam to communicate approved medical materials to external stakeholders
  • Discuss why medical affairs groups in pharmaceutical companies ignore digital influencers at their own risk and how identifying, engaging and collaborating with digital influencers in the healthcare provider community has moved from being cutting-edge to being an essential part of every expert engagement strategy
  • Following experts who share information and opinions on social media to stay on top of information relevant to their therapeutic areas, clinical trials, treatment options as well discussions about their and their competitors’ drugs
  • Ensuring HCPs have access to the most up to date information by co-creating social media content that is helpful and addresses the HCP’s pain points
A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speakers may have questions for you as well!